I

Integra LifeSciences

Regenerative medicine, surgical devices provider

Tender and Contracts Associate

Full-TimeUpdated on 10/23/2026
No salary listed
Mid
Remote in UK
RemoteUK remote; expected travel 5–10%.
Contract Management

About the job

Requirements
  • Experience working within commercial functions such as sales support, tender coordination, or marketing.
  • Experience with project management and contract management.
  • Experience working within a fast-paced, multifunctional environment.
  • Experience with Oracle, Power BI, Excel, and Salesforce.
  • Commercial awareness and customer care experience.
  • Proven experience establishing successful key relationships and delivering excellent standards of customer service.
  • Fluency in spoken and written English.
  • Ability to communicate clearly and effectively in oral and written forms, listen actively, interact with people at all levels of authority, tailor messages to audiences, and present information to individuals and groups.
  • Ability to prioritize tasks efficiently and productively and manage time well.
  • Ability to take a logical and analytical approach to problem-solving, generate workable solutions, and resolve issues or challenging situations.
  • Ability to work independently and proactively on one's own initiative.
  • Ability to build trusting relationships with customers and colleagues and work collaboratively to achieve business goals.
  • Ability to adapt positively to changing conditions, priorities, and workloads and to manage multiple concurrent tasks or projects independently or as part of a team.
  • Ability to prioritize customer satisfaction and establish effective customer relationships that gain trust and respect.
  • Accuracy and strong attention to detail.
Responsibilities
  • Manage post-award tender and contract tasks and special projects across the EMEA region as instructed by the Tender and Contracts Senior Manager.
  • Manage customer requests set out in tenders, working with the Insights and Pricing team to ensure knowledge transfer and coordinate tasks.
  • Administer and own the Distributor Agreements process, coordinating with senior leaders in Legal, Compliance, and Quality, and supporting Go to Market and the Senior Director for Commercial Operations as requested.
  • Oversee contract maintenance and communicate with key stakeholders, including internal teams and customers at appropriate management levels.
  • Review the tender pipeline monthly for expired contract modifiers and commercial agreements to ensure accuracy and compliance, and provide timely updates to Country Managers and the wider Commercial Operations team.
  • Act as the first point of contact for tender pricing discrepancies and ensure timely resolution and reduced errors across markets.
  • Support and maintain customer data portals and other relevant customer platforms used across EMEA.
  • Collaborate with internal stakeholders, including Legal, Regulatory, Sales, and Marketing teams, to keep tender and contract documentation current and compliant.
  • Assist with other tasks or projects across EMEA as assigned by the Line Manager or wider Commercial Operations team.
  • Support the pre-award team on strategic tenders.
  • Monitor and coordinate tender portal notifications and communications.
  • Travel for business as needed; the role is UK remote with an expected travel commitment of 5–10%.
Desired Qualifications
  • Fluency in French, German, Italian, or Dutch is an asset.

About the company

Integra LifeSciences develops medical technologies for tissue repair and regeneration, including tissue-regeneration scaffolds, neurosurgical devices, wound care products, and specialized surgical instruments. Its scaffolds are implanted on wounds to provide a temporary matrix that guides new tissue growth and gradually integrates with the patient's tissue. The company differentiates itself through a diversified, multi-domain portfolio built via acquisitions, spanning regenerative medicine and conventional medical devices. Its goal is to broaden access to regenerative technology and raise standards of care in surgery and tissue repair.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Plainsboro Township, New Jersey

Founded

1989

Get referred to Integra LifeSciences

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue reached $391.9 million, with organic growth and raised EPS guidance.
  • S&P upgraded Integra to B on October 1, 2026, citing normalization progress.
  • Management targets $200 million operating cash flow in 2026, aided by cost savings.

What critics are saying

  • Cincinnati flooding cuts Q3 revenue $7 million and Q4 revenue $15 million to $20 million.
  • The Cincinnati plant returns only in Q2 2027, extending customer loss and backlog risk.
  • Boston cGMP securities litigation threatens damages, injunctions, and existential brand erosion.

What makes Integra LifeSciences unique

  • Integra spans neurosurgery, wound care, and reconstructive biologics, reducing single-product dependence.
  • Braintree's June 2026 ramp and Q4 2026 SurgiMend relaunch restore proprietary supply control.
  • 2027 Liberties launch and SurgiMend PMA target create new neurosurgery and breast-reconstruction wedges.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Medical Insurance
  • Dental Insurance
  • Vision Insurance
  • Short-Term Disability
  • Long-Term Disability
  • 401(k) Retirement Plan

Growth & Insights and Company News

6 month growth

0%

1 year growth

4%

2 year growth

4%
Yahoo Finance
Oct 22nd, 2026
Integra LifeSciences shares fall 11% despite $411.2M Q3 revenue and return to profit

Integra LifeSciences shares fell about 11% in the first full session after its third-quarter 2026 results, as investors focused on refinancing worries and a high price-to-earnings ratio. Revenue rose to $411.2 million from $402.1 million a year earlier. The company posted a net profit of $14.9 million, against a $5.4 million loss, or basic earnings per share of $0.19. Operating cash flow reached $96 million, and net leverage fell to 3.8x. Net debt remains about $1.6 billion. Integra plans to refinance through new $450 million 9.5% notes, at an estimated 100 to 200 basis points higher rate. It also forecasts higher interest costs in 2027 and a softer fourth-quarter organic outlook.

Associated Press
Oct 9th, 2026
Integra prices $450M senior secured notes at 9.5% to refinance credit facilities

Integra LifeSciences Holdings Corporation has priced $450 million in senior secured notes due 2033, carrying a 9.500% interest rate. The medical technology company expects to close the sale on or around 19 October 2026, subject to customary closing conditions. The notes will be general senior secured obligations guaranteed by Integra's wholly-owned domestic subsidiaries that guarantee the company's existing senior secured credit facilities. Integra plans to use proceeds from the offering, combined with borrowings under new credit facilities, to refinance existing credit facilities and cover associated fees and expenses. The offering forms part of a broader refinancing transaction. The notes were offered only to qualified institutional buyers and certain non-US persons, relying on exemptions from Securities Act registration requirements. Integra LifeSciences is a global medical technology company specialising in neurosurgery and tissue reconstruction.

Associated Press
Oct 2nd, 2026
Integra LifeSciences cuts 2026 guidance after Cincinnati flooding disrupts production

Integra LifeSciences has lowered its full-year 2026 financial guidance following flooding at its Cincinnati manufacturing facility in July. The medical technology company now expects annual revenue of $1.634 billion to $1.654 billion, down from previous guidance of $1.654 billion to $1.695 billion. The flooding disrupted production of several products in the company's Specialty Surgical Technologies portfolio. Integra estimates the supply disruption reduced third quarter revenue by approximately $7 million and will impact fourth quarter revenue by $15 million to $20 million. The company expects third quarter revenue of $410 million to $412 million and adjusted earnings per share of $0.55 to $0.59. Full-year adjusted earnings per share guidance has been revised to $2.30 to $2.40, down from $2.40 to $2.50. Integra maintains property and business interruption insurance and expects recoveries to mitigate a substantial portion of the earnings impact. The facility is expected to return to full manufacturing operations during the second quarter of 2027.

MarketScreener
Oct 2nd, 2026
Integra LifeSciences Launches $600 Million Senior Secured Term Loan B

Integra LifeSciences said Friday that it has launched a $600 million seven-year senior secured term loan B as part of a broader refinancing transaction. The medical technology company said it...

Yahoo Finance
May 29th, 2026
Integra LifeSciences shares jump 6% after Citigroup upgrades rating and raises price target to $16

Integra LifeSciences shares rose 6.1% after Citigroup upgraded its rating from Sell to Neutral and raised its price target to $16 from $11. Analyst Joanne Wuensch's upgrade reflects reduced downside risk, though not yet a bullish outlook. The upgrade follows strong first-quarter 2026 results reported 22 days earlier, when the stock gained 5.3%. Integra's revenue grew 2.4% year-on-year to $391.9 million, beating estimates, whilst adjusted earnings per share of $0.54 exceeded consensus by 32.8%. The company raised its full-year earnings guidance and appointed Stuart Essig as CEO. Integra shares are up 36.7% year-to-date and recently hit a 52-week high of $16.42, though five-year returns remain significantly negative.